ONCOS-102
AXP000035.1 · Oncolytic virus
- Platform
- adenovirus (Ad5/3 chimera, Delta-24, E3 gp19k/6.7k replaced by GM-CSF)
- Originator
- Oncos Therapeutics
- Sponsor
- Targovax
Names
| Name | Type | Source |
|---|---|---|
| ONCOS-102 | preferred name, code | curator, ncit |
| Ad5/3-D24-GMCSF | synonym | paper |
| CGTG-102 | former code | ncit |
Virus
- Role
- Oncolytic
- Family
- Adenoviridae
- Virus
- human adenovirus 5 (NCBI Taxonomy 28285)
- Strain
- Ad5/3 chimera
- Replication
- conditionally replicating
- Modifications
- 24-bp E1A CR2 deletion; Ad3 fiber knob; GM-CSF in place of E3 gp19k/6.7k
- Transgenes
- CSF2
- Route
- intratumoral, intraperitoneal
- Source
- evidence
Cross-references
- NCI Thesaurus
- C98287
Approvals
No regulatory approval recorded.
Clinical trials (7)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT05561491 | A Study of ONCOS-102 in Combination With Other Novel Immune-therapies in Advanced Treatment-resistant Melanoma Patients | Withdrawn | Phase 2 | 2024-01 | 2027-06 | 0 | Melanoma |
| NCT03514836 | A Phase I/II, Safety Clinical Trial of DCVAC/PCa and ONCOS-102 in Men With Metastatic Castration-resistant Prostate Cancer | Terminated | Phase 1/2 | 2018-05-23 | 2021-01-25 | 5 | Castration-resistant Prostate Cancer |
| NCT02963831 | A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies | Completed | Phase 1/2 | 2017-09-07 | 2022-06-25 | 67 | Appendiceal Cancer; Colorectal Cancer; Ovarian Cancer |
| NCT03003676 | A Pilot Study of Sequential ONCOS-102, an Engineered Oncolytic Adenovirus Expressing GMCSF, and Pembrolizumab in Patients With Advanced or Unresectable Melanoma Progressing After Programmed Cell Death Protein 1 (PD1) Blockade | Completed | Phase 1 | 2016-12 | 2020-07 | 21 | Advanced or Unresectable Melanoma Progressing After PD1 Blockade |
| NCT02879669 | A Randomised Phase II Open-label Study With a Phase Ib Safety lead-in Cohort of ONCOS-102, an Immune-priming GM-CSF Coding Oncolytic Adenovirus, and Pemetrexed/Cisplatin in Patients With Unresectable Malignant Pleural Mesothelioma | Unknown | Phase 1/2 | 2016-06 | 2020-05 | 31 | To Determine Safety, Tolerability and Efficacy of ONCOS-102 in Combination With Chemotherapy |
| NCT01598129 | ONCOS-102 (Previously CGTG-102) for Therapy of Advanced Cancers | Completed | Phase 1 | 2012-04 | 2013-10 | 12 | Malignant Solid Tumour |
| NCT01437280 | GOAT; Phase I Open Label Study of CGTG-102, a GM-CSF Encoding Oncolytic Adenovirus, for Advanced Cancers | Withdrawn | Phase 1 | 0 | Solid Tumors; Tumors |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 37661097 | ONCOS-102 plus pemetrexed and platinum chemotherapy in malignant pleural mesothelioma: a randomized phase 2 study investigating clinical outcomes and the tumor microenvironment. | Journal for immunotherapy of cancer | 2023 | name in title: ONCOS-102 |
| PMID 30713786 | Combination of immunogenic oncolytic adenovirus ONCOS-102 with anti-PD-1 pembrolizumab exhibits synergistic antitumor effect in humanized A2058 melanoma huNOG mouse model. | Oncoimmunology | 2019 | cited by trial NCT03003676 |
| PMID 26981247 | Phase I study with ONCOS-102 for the treatment of solid tumors - an evaluation of clinical response and exploratory analyses of immune markers. | Journal for immunotherapy of cancer | 2016 | cited by trial NCT01598129 |
| PMID 23493351 | Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2013 | name in abstract: Ad5/3-D24-GMCSF |
| PMID 20664527 | Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF. | Molecular therapy : the journal of the American Society of Gene Therapy | 2010 | name in abstract: Ad5/3-D24-GMCSF |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 42397418 | EGFRxCD16 bispecific antibodies orchestrate superior NK cell-mediated lysis of ovarian cancer and NSCLC cell lines in combination with oncolytic viruses. | Cancer immunology, immunotherapy : CII | 2026 | name in abstract: ONCOS-102 |
| PMID 39941870 | A Meta-Analysis of First-Line Treatments for Unresectable Pleural Mesothelioma: Indirect Comparisons from Reconstructed Individual Patient Data of Six Randomized Controlled Trials. | Cancers | 2025 | name in abstract: ONCOS-102 |
| PMID 38454393 | Inducing expression of ICOS-L by oncolytic adenovirus to enhance tumor-specific bi-specific antibody efficacy. | Journal of translational medicine | 2024 | name in abstract: ONCOS-102 |
| PMID 36112545 | Pilot Study of ONCOS-102 and Pembrolizumab: Remodeling of the Tumor Microenvironment and Clinical Outcomes in Anti-PD-1-Resistant Advanced Melanoma. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2023 | name in title: ONCOS-102 |
| PMID 36269283 | ONCOS-102: A Step Forward or Sideways? | Clinical cancer research : an official journal of the American Association for Cancer Research | 2023 | name in title: ONCOS-102 |
| PMID 34277838 | Current status of intralesional agents in treatment of malignant melanoma. | Annals of translational medicine | 2021 | name in abstract: ONCOS-102 |
| PMID 31944306 | Chimeric oncolytic Ad5/3 virus replicates and lyses ovarian cancer cells through desmoglein-2 cell entry receptor. | Journal of medical virology | 2020 | name in abstract: ONCOS-102 |
| PMID 31081549 | Abscopal effect when combining oncolytic adenovirus and checkpoint inhibitor in a humanized NOG mouse model of melanoma. | Journal of medical virology | 2019 | name in abstract: ONCOS-102 |
| PMID 29797583 | Antitumor-specific T-cell responses induced by oncolytic adenovirus ONCOS-102 (AdV5/3-D24-GM-CSF) in peritoneal mesothelioma mouse model. | Journal of medical virology | 2018 | name in title: ONCOS-102 |
| PMID 28796812 | Toxicological and bio-distribution profile of a GM-CSF-expressing, double-targeted, chimeric oncolytic adenovirus ONCOS-102 - Support for clinical studies on advanced cancer treatment. | PloS one | 2017 | name in title: ONCOS-102 |
| PMID 27057453 | Oncolytic virotherapy for treatment of breast cancer, including triple-negative breast cancer. | Oncoimmunology | 2016 | name in abstract: Ad5/3-D24-GMCSF |
| PMID 27287512 | Synergistic anti-tumor efficacy of immunogenic adenovirus ONCOS-102 (Ad5/3-D24-GM-CSF) and standard of care chemotherapy in preclinical mesothelioma model. | International journal of cancer | 2016 | name in title: Ad5/3-D24-GMCSF |
| PMID 28051835 | Mesothelioma and interferon-γ-dependent chemokine IP-10. | La Clinica terapeutica | 2016 | name in abstract: ONCOS-102 |
| PMID 24975392 | Oncolytic adenovirus and doxorubicin-based chemotherapy results in synergistic antitumor activity against soft-tissue sarcoma. | International journal of cancer | 2015 | name in abstract: Ad5/3-D24-GMCSF |
| PMID 25821063 | Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GM-CSF: Results in vitro, in rodents and in humans. | International journal of cancer | 2015 | name in abstract: Ad5/3-D24-GMCSF |
| PMID 26140248 | Repeated intratumoral administration of ONCOS-102 leads to systemic antitumor CD8+ T-cell response and robust cellular and transcriptional immune activation at tumor site in a patient with ovarian cancer. | Oncoimmunology | 2015 | name in title: ONCOS-102 |
| PMID 24374597 | Serotype chimeric oncolytic adenovirus coding for GM-CSF for treatment of sarcoma in rodents and humans. | International journal of cancer | 2014 | name in abstract: Ad5/3-D24-GMCSF |
| PMID 25941579 | Local treatment of a pleural mesothelioma tumor with ONCOS-102 induces a systemic antitumor CD8+ T-cell response, prominent infiltration of CD8+ lymphocytes and Th1 type polarization. | Oncoimmunology | 2014 | name in title: ONCOS-102 |
| PMID 20582867 | American Society of Gene & Cell Therapy--13th Annual Meeting. | IDrugs : the investigational drugs journal | 2010 | name in abstract: CGTG-102 |
NIH grants
| Project | Title | Organisation | PI | Years | Linked by |
|---|---|---|---|---|---|
| K00CA274650 | Defining tumor and blood-based immunogenomic signatures predicting response to immunotherapy in ovarian cancer | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | MONSON, KELSEY R | 2025–2026 | name in abstract: ONCOS-102 |
| R01CA269382 | POTENTIATION OF ANTI-TUMOR IMMUNITY BY ONCOLYTIC VIRUS IN SITU VACCINATION | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | ZAMARIN, DMITRIY | 2023–2026 | name in abstract: ONCOS-102 |
Notes
Development code CGTG-102; the same construct was given to ATAP patients in Finland as Ad5/3-D24-GMCSF before Oncos Therapeutics was formed. Oncos Therapeutics merged with Targovax in 2015. Targovax deprioritised its oncolytic adenovirus programme around 2022-2023; current status not confirmed from a primary source.
How to cite
ONCOS-102 (AXP000035.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000035.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.